Schering Aktiengesellschaft

Medimmune Limited

Amgen Fremont Inc.

Pfizer Corporation

Amgen Inc.

Astrazeneca Ab

Abbott Laboratories Corporation

Celldex Therapeutics Limited

Abgenix, Inc.

Curagen Corporation

Meina Liang

Wei Xu

Howard P Ng

Michael M Morrissey

Brad Owen Buckman

Sean D Monahan

John G Bauman

Guo Ping Wei

Imadul Islam

Richard Horuk

Joseph E Hesselgesser

Karen B May

Ameen F Ghannam

Wei Zheng

Zuchun Zhao

Kenneth Jay Shaw

Orit Foord

Yen-Wah Lee

Mary Haak-Frendscho

Brandon Higgs

Koustubh Ranade

Larry L Green

Raffaella Faggioni

Katie Streicher

Carlos Chavez

Jean M Gudas

Scott L Klakamp

Lorin Roskos

David Fairman

Marlon Rebelatto

Kiran Ahluwalia

Rajesh Narwal

Paul Robbins

Amy Schneider

Carina Herl

Min Pak

Hong Lu

Keith Steele

Anmarie Boutrin

Li Shi

Shengyan Hong

Sunil Bhakta

Ethan Grant

Arvind Rajpal

Jaspal Singh Kang

Partha S Chowdhury

John Stephen Babcook

Xiao Feng

Jing Li

Qiaojuan Jane Su

Ronald P Gladue

Palaniswami Rathanaswami

Giorgio Senaldi

Reena Varkey

Bradley T Keller

Kathy Manchulenko

Yihong Yao

Shelley Sims Belouski

Chris Morehouse

William Rees

Lydia Greenlees

Robert W Georgantas, Iii

Shinji Ogawa

Craig Pigott

Inna Vainshtein

Melissa Parker

Jingjing Chen

Robert A Gasser, Jr

Laurie A Tylaska

Gary Bruce Phillips

Xiao-Chi Jia

Michael Torgov

Henri Lichenstein

Stefan Jaroch

Monica J Kochanny

Bin Ye

Peter S Mezes

Susan E Brophy

Luca Rastelli

James Onuffer

Xiongdong Lian

Michael Jeffers

Wheeseong Lee

John L Herrmann

William LaRochelle

Bruce J Dille

Juan Davagnino

Tomas M Mustelin

Kam Fai Tse

Gerard Davis

Feng Xiao

Vincent A Pollack

Gulshan Ara

Andrei Chapoval

Cyrus Karkaria

Laura Dunning

Shou-Fu Lu

Guo-Ping Wei

Rachel Patricia Moate

Alex Godwood

Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.

Anti-B7-H1 antibodies for treating tumors

The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.

Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis

The present invention relates to the use of the Chemokine (C&#x2014;C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).

CCL20 as a predictor of clinical response to IL23-antagonists

The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.

Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.

Methods of using antibodies to determine periostin levels in a sample

Monoclonal antibodies which bind human periostin

Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.

Nucleic acids encoding antibodies to CCR2

The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

Antibodies directed to GPNMB and uses thereof

Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen binding portions thereof.

Antibodies to CCR2

Antibodies directed to the antigen TNF&#x3b1; and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNF&#x3b1;. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

Antibodies directed to tumor necrosis factor and uses thereof

Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof

Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Antibodies directed to tumor necrosis factor

Growing community of inventors

Danville, CA, United States of America

Meina Liang